Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT plus zimberelimab for melanoma brain metastases (Phase II, single-arm)
ChiCTR2200057001Phase 2Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab in melanoma and brain metastases, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Intracranial objective response rate. Started Oct 2022; status: completed.
02
Drugs
zimberelimab
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on ChiCTR2200057001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057001.